Experts dub doctor’s stem cell technique flawed, fraudulent

Like India, Sri Lanka’s scientific community doesn’t sanction stem cell therapy as a treatment for neurodevelopmental disorders, but there are no laws prohibiting it.

Alleging that Sion Hospital’s Dr Alok Sharma screened patients in a Colombo hotel after delivering a talk on the subject, the Sri Lanka College of Paediatricians (SLCP) put out a public notice warning people from falling prey to “unproven and exploitative therapies”.

Speaking to TOI, SCLP member Dr Samanmali Sumanasena expressed anger at Dr Sharma allegedly marketing the therapy for sums nearing Rs 6.6 lakh. “He or the company (NeuroGen Brain and Spine Institute, Navi Mumbai) had no authority to screen patients in our country without our medi council’s approval,” she said.

Dr Sharma is unfazed by the uproar. “The Lankan community has reacted just the way Indian doctors have over the years. We have MRI and PET scans of 1,200 children to show how stem cells have improved the problematic areas of the brain in autistic children. Nearly a third of these children have gone out of the autism spectrum.”

Explaining the technique, he said he injects stem cells derived from the bone marrow of such children and therefore it’s absolutely safe. But this very mechanism has been dubbed as flawed and even fraudulent by experts. Paediatric neurologist Dr Vrajesh Udani said, “Researchers have zeroed down on 11 genes that are believed to be involved in the pathogenesis of autism. Hence, whatever genetic defects a child has will also be present in the bone marrow. Also, it is unethical to charge patients for an experimental therapy.”

ICMR’s member Dr Geeta Jotwani said its guidelines don’t approve of stem cell use for autism (see graphic). “We framed norms keeping international regulations and research advances in mind,” she said. “The guidelines have a provision for clinical trials as well.” But Dr Sharma implied that conducting a clinical trial would mean depriving some children from stem cell therapy “that works”.

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    IndiaAI, ICMR sign MoU to advance AI in healthcare

    IndiaAI, ICMR sign MoU to advance AI in healthcare

    Illegal drug manufacturing racket busted in Baddi area

    Illegal drug manufacturing racket busted in Baddi area

    US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

    US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

    Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

    Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

    Six Women Develop Serious Complications After C-Section

    Six Women Develop Serious Complications After C-Section

    Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected

    Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected